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SUMMARY 
The COVID-19 pandemic is an ongoing global challenge for public health systems. 
Ultrasensitive and early identification of infection is critical to prevent widespread COVID-
19 infection by presymptomatic and asymptomatic individuals, especially in the community 
and in-home settings. We demonstrate a multiplexed, portable, wireless electrochemical 
platform for ultra-rapid detection of COVID-19: the SARS-CoV-2 RapidPlex. It detects viral 
antigen nucleocapsid protein, IgM and IgG antibodies, as well as the inflammatory biomarker 
C-reactive protein, based on our mass-producible laser-engraved graphene electrodes. We 
demonstrate ultrasensitive, highly selective, and rapid electrochemical detection in the 
physiologically relevant ranges. We successfully evaluated the applicability of our SARS-
CoV-2 RapidPlex platform with COVID-19 positive and negative blood and saliva samples. 
Based on this pilot study, our multiplexed immunosensor platform may allow for high 
frequency at-home testing for COVID-19 telemedicine diagnosis and monitoring. 
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INTRODUCTION 
On March 11, 2020, the World Health Organization characterized the COVID-19 outbreak as 
a pandemic. Six months later, the global health crisis had continued with over 30 million 
confirmed cases of novel coronavirus globally – over 22% of these were in the United 
States.1 It is estimated that 14-20% of patients will develop severe illness requiring 
hospitalization.2 Initial efforts to mitigate the spread through state-mandated “stay-at-home” 
orders appeared effective, however, reopening of the US economy resulted in renewed 
exponential spread of novel coronavirus, as predicted.3 It is estimated that the US GDP will 
suffer losses upwards of $45.3 billion during a flu-like pandemic without available vaccines.4 
Safe reopening of the economy, schools and universities requires multiple approaches to 
mitigate the risks associated with COVID-19, including simple, affordable and effective test-
and-trace measures. 
Containing the spread is difficult due to the challenges in identifying infectious individuals. 
Most COVID-19 community spread may occur in the absence of symptoms. Peak viremia 
may be at the end of the incubation period, allowing for a transmission-sufficient viral load 1-
2 days prior to symptom onset.3 Additionally, due to the unknown duration and prevalence of 
asymptomatic cases, the true reproduction number may be under-estimated.5,6 Reported 
incidence of asymptomatic patients ranges from 17.9% to 30.8%.7,8 
Increased access to COVID-19 testing has allowed increased monitoring of the community 
spread, but several diagnostic challenges remain. Currently, the standard testing method is 
viral nucleic acid real-time polymerase chain reaction (RT-PCR), which is a slow 
process9 and requires expensive equipment and trained technicians for nasopharyngeal swab 
sample collection and analysis.9 In addition, the sheer volume of testing required is 
overwhelming the ability for healthcare systems to report RT-PCR results to patients, causing, 
in some states, delays of ~7-10 days to inform positive10 findings and enact isolation and 
monitoring protocols. Despite the recent advances on point-of-care (POC) rapid RT-PCR 
test,11–15 nucleic acid tests are also known to produce false negatives, which may limit 
containment strategies and access to treatment.16 An additional consideration for RT-PCR is 
that it only identifies active carriers of the virus. Identifying convalescent persons based on 
COVID-19 antibody presentation is equally important as it may provide health officials with 
crucial information regarding the potential impact of reopening measures.17 Serologic assays 
detect circulating antibodies specific to SARS-CoV-2 antigens, including the nucleocapsid 
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protein and the outer spike protein.9,18 However, it is not possible to differentiate between 
asymptomatic carriers and immune persons using antibody detection. Therefore, to 
effectively mitigate the risks of COVID-19 community spread, systems are required that 
determine simultaneously both the viral and serologic status of an individual. Moreover, 
recent studies show correlation between circulating inflammatory biomarker concentration 
and COVID-19 severity.19 Increased C-reactive protein (CRP) concentration is found in 
patients diagnosed with COVID-19 pneumonia and is associated with increasing 
severity, suggesting a role in diagnosis and prognosis of COVID-19 patients.20,21 
There is a clear and urgent need for a highly sensitive, rapid, inexpensive, telemedicine 
COVID-19 test that can identify a patient’s past and present infection status.22 There has been 
progress towards POC COVID-19 testing, but all commercially available test kits provide 
only qualitative results. Quantitative analysis of COVID-19 biomarkers using a telemedicine 
device may provide predictive information of disease severity and provide seroconversion 
information regarding disease time course. Electrochemical biosensors, in this regard, are 
advantageous due to their rapid detection efficacy and ease of use for POC applications.23–27 
Simple, safe and effective COVID-19 sample collection has proved challenging given current 
assay requirements. Saliva-compatible POC assays would be advantageous since saliva 
contains rich information and can be easily and non-invasively collected by patients 
themselves for telemedicine testing.28  
Here, we present a novel multiplexed, portable, wireless electrochemical platform for ultra-
rapid detection of COVID-19: SARS-CoV-2 RapidPlex (Figure 1). This platform 
quantitatively detects biomarkers specific to COVID-19 in both blood and saliva including 
SARS-CoV-2 nucleocapsid protein (NP), specific immunoglobulins (Igs) against SARS-
CoV-2 spike protein (S1) (S1-IgM and S1-IgG), and CRP, within physiologically relevant 
ranges. The platform uses capture antigens and antibodies immobilized on mass-producible, 
low-cost laser-engraved graphene (LEG)29,30 electrodes. This multiplexed platform tracks the 
infection progression by diagnosing the stage of the disease, allowing for the clear 
identification of individuals who are infectious, vulnerable, and/or immune (Table 1). The 
main features of SARS-CoV-2 RapidPlex are high sensitivity, low cost, ultra-fast detection, 
wireless remote and multiplexed sensing that provides information on three key aspects of 
COVID-19 disease: viral infection (NP),31 immune response (IgG and IgM),9 and disease 
severity (CRP).19–21  
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RESULTS AND DISCUSSION 
Design of the SARS-CoV-2 RapidPlex Platform 
As illustrated in Figure 1A, SARS-CoV-2 RapidPlex is composed of four graphene working 
electrodes (WEs), a Ag/AgCl reference electrode (RE), and a graphene counter electrode 
(CE), all of them patterned on a polyimide (PI) substrate via CO2 laser engraving, a fast, 
high-throughput, and cost-effective production method (Figure 1B and 1C). Our group has 
recently demonstrated the use of mesoporous graphene structure fabricated by laser 
engraving for high performance and low-cost biosensing.29,30 The materials cost for the 
unmodified RapidPlex platform is within $0.05; additional chemical and reagent costs for the 
multiplexed sensor preparation are at the level of dollars depending on the order sizes. 
Detection of selected target proteins (NP and CRP) and specific immunoglobulins (S1-IgG 
and S1-IgM) is achieved through sandwich- and indirect-based immunosensing strategies 
onto the LEG electrodes, respectively. The superior properties of graphene, in terms of high 
charge mobility and surface area together with the high sensitivity and selectivity of sensing 
strategies involving both capture and detector receptors, make our device (Figure 1D) a 
highly convenient tool for the rapid, accurate, and stage-specific COVID-19 infection 
detection in blood as well as in non-invasive biofluid samples, such as saliva.  
Electrochemical Characterization of SARS-CoV-2 RapidPlex Platform 
Functionalization and modification steps carried out on the LEG surfaces for the covalent 
attachment of each of the specific receptors required for the development of our SARS-CoV-
2 RapidPlex platform is schematized in Figure 2A. 1-pyrenebutyric acid (PBA) is used as the 
linker to anchor the required receptors to the graphene layer. Although attachment of 
functional groups directly on the sp2 carbon atom surface is one of the common ways to 
functionalize graphene, these methods are associated with the requirement of defects or edges 
in the sensor material, which could alter its specific physical properties.32,33 In contrast, 
introduction of functional groups on the sensing layer by means of pyrene derivatives is 
preferred here as it does not disrupt the conjugation of the graphene sheets and improves its 
stability.34,35 PBA consisting of a pyrene group that contains π-electrons and a carboxylic 
group is used to functionalize graphene layers via π-stacking and hydrophobic interactions. 
The pyrene units of PBA strongly interact with graphene layers in the way that original 
structure and properties of the graphene are well maintained. The functional moieties 
contained in each PBA molecule allow the preparation of the affinity-based biosensing 
platform through the covalent coupling between the carboxylic groups on PBA units and the 
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–NH2 groups of the respective capture receptors (specific antibodies or capture proteins). 
Blocking of unreacted sites with bovine serum albumin (BSA) impedes the non-specific 
adsorption of other molecules involved in each assay configuration or circulating in the 
sample of interest. 
Differential pulse voltammetry (DPV) and open circuit potential-electrochemical impedance 
spectroscopy (OCP-EIS) techniques are employed to electrochemically characterize and 
prove the stepwise self-assembled processes in both assay configurations for the detection of 
selected target molecules. DPV readings reflect lower peak current intensity after each 
modification step related to S1-Ig assay due to the hindered diffusion of the redox label to the 
electrode surface derived from both the carboxyl groups and the attached proteins and 
biological macromolecules (Figure 2B). At the same time, resistance in the Nyquist plots 
from OCP-EIS is increased after each functionalization step (Figure 2C). The successful 
anchorage of PBA was also verified with scanning electron microscopy (SEM) (Figure S1). 
Electrochemical characterization of the sandwich assay-based sensor modification using CRP 
protein as a model molecule and the aforementioned techniques are presented in Figure S2. 
To preserve the native structure and properties of the bound biomolecules, PBA was chosen 
as a heterobifunctional linker, effectively preventing the direct interaction between large 
biomolecules and the graphene surface.33 In order to verify this selection, CRP and SARS-
CoV-2 specific IgG assay configurations were constructed on graphene electrodes 
functionalized with PBA and another common linker, 1H-pyrrole-1-propionic acid (PPA).30 
Greater signal-to-blank (S/B) ratios were observed for both assays where PBA was used as a 
linker support (Figure 2D), mainly due to a significant decrease in the signals obtained in the 
absence of the corresponding target molecule when PBA was used instead of PPA. Together 
with an optimal blocking strategy, PBA can be used for the immobilization of specific 
biomolecular probes (e.g. antibodies, proteins, etc.) while avoiding non-specific adsorptions 
in the context of immunoassays.36  
The orientation of modified antigenic proteins on solid surfaces is strongly associated with 
their activity and reactivity. Specific anti-His antibodies can be used to orient the 
immobilization of antigenic receptors containing histidine residues, but this implies an 
additional step compared with their direct attachment on the sensing layer, as it is 
schematized in Figure S3A. Our results show no significant differences in assay performance 
for IgG detection on PBA-graphene electrodes covalently functionalized with the specific 
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coating protein (direct immobilization) and with anti-His antibodies for the previous capture 
of the polyhistidine-tag specific coating protein (oriented immobilization) (Figure S3B), 
proving that random protein orientation does not interfere with the epitope accessibility for 
effective recognition by specific target antibodies. This is in agreement with other reports 
confirming that His-tagged fusion antigens can be directly immobilized on different surfaces 
with protein orientations completely compatible with antibody recognition.37–40 In order to 
simplify and reduce the cost and time of the assay, direct immobilization of S1 protein was 
carried out for specific Ig detection.  
Considering that rapid target binding is essential to the successful implementation of our 
proposed platform as a POC system, we investigated how target (or sample) incubation time 
affects the response of each biosensor comprising our SARS-CoV-2 RapidPlex platform. 
Figure 2E summarizes the amperometric signals obtained for each of the four sensing units 
at different incubation times (1, 5 and 10 minutes) in the absence (blank, B) and in the 
presence (S) of 500 pg mL-1, 250 ng mL-1, and 50 ng mL-1 of NP, SARS-CoV-2 specific IgG 
and IgM isotypes, and CRP, respectively. It is important to note that although a 10-minute 
incubation time was selected for most of the studies here in order to ensure the highest 
sensitivity for the determination of ultra-low levels of each target molecule, a significant 
difference between the absence and the presence of each of the corresponding targets is 
obtained with just 1-minute incubation time. This provides one of the major advantages of 
our SARS-CoV-2 RapidPlex system as a rapid POC device for SARS-CoV-2 infection 
monitoring with the required sensitivity for both protein and Ig determination. ELISA,17,41–44 
nucleic acid amplification,45–49 mass spectrometry,50 or even combinations51 have been 
reported very recently for determination of the proposed SARS-CoV-2 specific target 
molecules, among others. However, most of these methods show crucial pitfalls, mainly in 
terms of sample preparation, complexity, and expensive and bulky equipment requirements, 
that make them still highly difficult to be implemented as POC systems. Our device provides 
an attractive alternative to standard assays for protein determination, such as ELISA, because 
of its multiplexing capabilities, remote functionality and short sample-to-answer time. 
Evaluation of Analytical Performance of the SARS-CoV-2 RapidPlex 
The performance of each biosensor contained in the SARS-CoV-2 RapidPlex was 
characterized in phosphate-buffered saline (PBS) solutions supplemented with 1.0% of 
bovine serum albumin (BSA) by measuring the amperometric readout in the presence of 
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increased concentrations of NP, S1-IgG, S1-IgM, and CRP (Figure 3). The selected 
strategies for NP viral antigen and CRP proteins are based on double sandwich and sandwich 
configurations, respectively, as illustrated in Figure 3A. The sandwich-based immunoassays 
for antigen detection are, in general, highly sensitive due to the involvement of two different 
antibodies as capture and detector entities. According to the low levels that must be reached 
for NP and CRP in diluted serum and saliva (pg mL-1 to ng mL-1), we think these strategies 
are the most suitable to be implemented on our platform. Variation of cathodic currents with 
the concentration for NP and CRP in buffered solutions are presented in Figure 3B and 3C, 
respectively. S1-IgG and S1-IgM were detected based on indirect immunoassays (Figure 3D), 
which are considered highly suitable for detection of circulating macromolecules in antisera 
and other biofluids. Figure 3E and 3F show the calibration curves for S1 specific Ig 
determination (S1-IgG and S1-IgM, respectively) in buffered solutions. Reproducibility was 
demonstrated through the relative standard deviation (RSD) values obtained with different 
biosensors prepared in the same manner on different days. RSD values of 6.3%, 8.4%, 6.0% 
and 7.6% for 20 ng mL-1 CRP, 250 ng mL-1 S1-IgG, 250 ng mL-1 S1-IgM and 500 pg mL-1 
NP antigen (n=5) demonstrate good reproducibility in both device preparation and signal 
transduction. In addition, the sensors showed stable responses over a 5-day storage period at 
4 °C (Figure S5). We did not observe significant slope variations between data obtained in 
properly diluted human serum and in buffered solutions for the determination of each target 
analyte (for instance, the slope sensitivity value (16.28 nA mL ng-1) obtained for CRP as 
model analyte in PBS buffered solutions is nearly the same as that in diluted serum samples 
from a healthy volunteer (16.64 nA mL ng-1)); therefore, accurate quantification of the 
proposed target analytes can be carried out by conducting a simple interpolation of the 
cathodic readings obtained for each sample tested in the corresponding calibration curve 
constructed in buffered solution. 
Since diagnostic sensitivity and specificity of seroprevalence studies can be improved by 
using a mixture of antigenic proteins instead of a single protein,52,53 we modified graphene 
with a mixture of SARS-CoV-2 related antigens, NP and S1, to capture specific 
immunoglobulin isotypes against both antigens in the same WE. A calibration curve for (NP 
+ S1)-IgG detection is shown in Figure S4. Thus, this methodology can be tailored for 
detecting isotype-specific IgG (or IgM) or a combination of both Ig isotypes in the same 
sensing surface to better capture total Ig concentration and thus increase assay sensitivity 
across the patient population. 
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Investigation of the Selectivity and Multiplexed Performance of the SARS-CoV-2 
RapidPlex 
Human biofluids contain a complex and variable mixture of circulating molecules that could 
interfere with molecular sensing. In addition, negligible crosstalk between different working 
surfaces is an essential requirement to perform multiplexed detection readings accurately and 
meaningfully. Therefore, selectivity and crosstalk of the SARS-CoV-2 RapidPlex platform 
were evaluated. Amperometric readings obtained for each developed biosensor against non-
target molecules are presented in Figure 4A. We evaluated the specific binding for SARS-
CoV-2 biomarkers in comparison to biomarkers of similar coronaviruses, including SARS-
CoV and MERS-CoV. We observed no significant cross-reaction for NP, S1-IgG, S1-IgM 
and CRP assays in the presence of each tested interferent, including SARS-CoV-2 S1, SARS-
CoV S1, and CRP (for NP assay), SARS-CoV-2 NP-IgG, SARS-CoV IgG, MERS-CoV IgG, 
S1-IgG, and negative controls containing mixtures of IgG and IgM against both MERS-CoV 
and SARS-CoV (for S1-IgG and S1-IgM assays), and BNP, NP, SARS-CoV NP and SARS-
CoV S1 (for CRP assay), respectively. However, SARS-CoV NP viral antigen interferent 
provided a cathodic current corresponding to ~80% of the raw current obtained for the 
detection of the specific NP antigen. Spike, envelope, and membrane SARS-CoV-2 proteins 
share 76-95% sequence identity with those of SARS-CoV. This percentage homology is 
reduced to 30-40% for MERS-CoV. Similarly, since SARS-CoV-2 NP is 90% identical to 
SARS-CoV NP,17,54–56 the interference observed from SARS-CoV NP antigen was expected. 
However, the lack of selectivity in this particular case is not a major concern due to the 
absence of new SARS-CoV cases detected recently; therefore, it can be inferred that this 
interference will not produce a barrier for selective SARS-CoV-2 NP determination in real 
samples. We further evaluated the amperometric-derived concentrations with absorbance-
derived concentrations collected via ELISA. As it is presented in Figure 4B, the results from 
our functionalized electrochemical biosensor were linearly correlated (r = 0.955) with the 
results using the same reagents in a traditional ELISA protocol. 
Once the performance and selectivity of each constructed biosensor was individually and 
exhaustively evaluated, we demonstrate the multiplexing capabilities of our four-working-
electrode (4WEs) graphene array device designed with a Ag/AgCl RE and a graphene CE. 
The block diagram showing the functional units that comprise the integrated electronic 
system is illustrated in Figure 4C and 4D. Amperometric readings from the four channels are 
concurrently taken and data is wirelessly transmitted to a user device over Bluetooth Low 
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Energy. The electronic system, including the printed circuit board (PCB) and a lithium-ion 
polymer battery, is 20 × 35 × 7.3 mm in dimension. The compact device can perform 
amperometric measurements continuously for over 5 hours in a single charge.  
With the objective of demonstrating the utility of our SARS-CoV-2 RapidPlex array for 
multiplexed and simultaneous quantification of selected target molecules, we evaluated the 
potential cross-reaction resulting from the diffusion of signal substances between adjacent 
immunosurfaces. For this, each of the four conveniently functionalized working surfaces 
were incubated with buffered solutions containing significantly high concentration of each of 
the selected targets, followed by the corresponding detector receptors in each case. The 
absence of cross-talk between the adjacent working electrodes is verified from the 
experimental readings in buffered solutions containing 1.0 ng mL-1 NP antigen (I), 250 ng 
mL-1  S1 specific IgG (II) and -IgM (III), and 50 ng mL-1 CRP (IV) (Figure 4E). As 
envisaged, significantly higher signal was obtained when each target was specifically 
captured and further labeled by its tracer antibody in the corresponding functionalized 
immunosurface. These results, in conjunction with those from Figure 4A demonstrate the 
feasibility of the developed SARS-CoV-2 RapidPlex platform for fast, selective and reliable 
determination of NP, S1-IgG and S1-IgM isotypes, and CRP in one single experiment. It 
should be noted that since IgG and IgM have similar binding mechanisms to viral antigens 
and individual quantification of Igs require no mixing of the specific detector labels, 
individual droplets were used on IgG and IgM sensing electrodes during modification and 
labelling.  
Detection of SARS-CoV-2 Related Selected Targets in Human Biospecimens 
To prove the utility of our device in a more complex and real scenario, we evaluated the 
multiplexed capabilities of SARS-CoV-2 RapidPlex in representative serum samples from 
COVID-19 RT-PCR negative and positive subjects. Sensor data from the serum samples of a 
RT-PCR negative subject (Figure 5A) and a RT-PCR positive patient (Figure 5B) show 
minimal cross-talk in a real and complex sample matrix, indicating the efficient functionality 
of SARS-CoV-2 RapidPlex to simultaneously differentiate the overexpressed presence of 
SARS-CoV-2 related target reporters in COVID-19 positive specimens. Moreover, the 
SARS-CoV-2 RapidPlex device is able to provide significant positive readings for all targets 
after incubating the COVID-19 positive serum sample for just 1 minute (Figure 5C and 
Figure S5): The maintained high signal in positive patient samples demonstrates the great 
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potential in future translation of the SARS-CoV-2 RapidPlex device as an ultra-fast POC 
remote diagnostic tool.  
To further investigate NP, S1-IgG, S1-IgM, and CRP response to SARS-CoV-2 infection 
using our LEG-based biosensors, each target molecule was measured in serum and saliva 
samples from RT-PCR confirmed COVID-19 positive and negative subjects. Obtained results 
were plotted as the ratio between the amperometric readings for each sample tested (S) and 
the respective blank (B) in each case to compare target detection in different concentration 
ranges. Using the graphene sensors, a total of 17 COVID-19 RT-PCR tested serum samples 
(10 positive, 7 negative) were assayed, and a total of 8 COVID-19 RT-PCR tested saliva 
samples (5 positive, 3 negative) were analyzed (Table S1).  
Results from Figure 5D and 5E corroborate that, as expected, compared to RT-PCR negative 
subjects, RT-PCR positive COVID-19 patients show significantly elevated levels of the 
selected targets in both serum and saliva samples, with median S/B ratios of 10.53, 11.62, 
10.67 and 12.39 in serum, and 2.81, 3.24, 1.62, and 1.76 in saliva, for NP, S1-IgG, S1-IgM, 
and CRP, respectively. We observed a concentration of NP in the range of 0.1-0.8 μg mL-1 
and 0.5–2.0 ng mL-1 in COVID-19 patient serum and saliva, respectively; S1-IgG in the 
range of 20–40 μg mL-1 and 0.2–0.5 μg mL-1 in COVID-19 patient serum and saliva, 
respectively; S1-IgM in the range of 20–50 μg mL-1 and 0.6–5.0 μg mL-1 in COVID-19 
patient serum and saliva, respectively; and CRP in the range of 10–20 μg mL-1 and 0.1–0.5 
μg mL-1 in COVID-19 patient serum and saliva, respectively. The factor that all the positive 
samples show much higher signals compared to negative samples proves the real utility for 
the accurate evaluation of the COVID-19 biomarkers in biofluids using our LEG-based 
biosensors. In particular, the observed significant presence of COVID-19 biomarkers in 
saliva demonstrates the great utility of this biofluid as a valuable source for non-invasively 
diagnosing and monitoring SARS-CoV-2 infection.  
With the aim to confirm the relationship between the levels of inflammatory biomarkers 
involved in the cytokine storm directly associated with disease progression, severity and 
outcome in COVID-19,57–62 we evaluated the variation of serum CRP levels in RT-PCR 
negative subjects (n=7) and RT-PCR positive COVID-19 patients who were classified 
clinically according to disease severity as asymptomatic (n=2), mild (n=5), moderate (n=2). 
As shown in Figure 5F, we observed a positive association between CRP concentration and 
COVID-19 symptom severity grade, consistent with the recent literature reports.20,61 Future 
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clinical testing using paired saliva and serum samples over the course of the infection is 
required to determine the relationship between saliva and serum concentrations and validate 
the utility of our platform in identifying severity-specific COVID-19 (Table 1). 
CONCLUSIONS 
To address the increasing demands for effective diagnostic tools for simple COVID-19 
detection with immediate sample-to-answer turnaround, we have developed and implemented 
the first multiplexed electrochemical graphene-based platform, SARS-CoV-2 RapidPlex, for 
sensitive, rapid and selective simultaneous interrogation of NP viral antigen, S1-IgG and -
IgM isotypes, and CRP in serum and saliva biofluids from healthy and RT-PCR confirmed 
COVID-19 infected patients. The combination of the advantageous properties of graphene 
material with the high sensitivity and specificity of the immunosensing strategies makes our 
SARS-CoV-2 RapidPlex platform a promising diagnostic device for the accurate monitoring 
of COVID-19 infection in serum and non-invasively accessible body fluids free from 
complex sample pretreatment requirements. Due to the ease of use, saliva sample 
compatibility, and rapid time to results, the SARS-CoV-2 RapidPlex platform has high 
potential for implementation at POC for patient triage, as well as for at-home use for 
telemedicine care and remote monitoring. 
Monitoring of selected targets in one single and fast experiment (target capture can be as low 
as 1 minute) provides substantial information not only regarding early COVID-19 infection 
through viral antigen and IgM isotype detection, but also about disease severity by means of 
CRP evaluation and potential acquired immunity through IgG isotype quantification. The 
rapid on-site evaluation of disease severity enabled by our SARS-CoV-2 RapidPlex 
introduces the unparalleled advantage of immediate COVID-19 triaging. In future clinical 
applications, this could not only alert attending physicians of cases requiring major and 
careful medical attention but also facilitate the efficient allocation of precious medical 
resources, such as ventilators and ICU beds, in the event of resurging outbreaks to optimize 
patient outcomes under an overloading of local healthcare systems. 
Our proposed methodologies based on simple, yet well-established surface functionalization 
techniques and sensing principles allow the ease of translation to the detection of other highly 
informative SARS-CoV-2 related reporters just by simply changing the coating capture 
receptor. Further technological improvement could be achieved by introducing fully 
automated sample handling process through a microfluidic module for telemedicine 
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deployment. Modification of our platform design may allow for rapid viral antigen and 
antibody panel testing such that COVID-19 infection could be clearly distinguished from 
non-specific symptoms of seasonal respiratory infections, such as influenza. Additionally, the 
wireless telemedicine diagnostic platform when coupled with emerging wearable biosensors 
to continuously monitor vital signs and other chemical biomarkers could provide 
comprehensive information on an individual’s health status during the COVID-19 
pandemic.63–67  
Our platform pioneers multiplexed detection of stage-specific SARS-CoV-2 related 
biomarkers to provide a detailed and personalized snapshot of the COVID-19 infection. We 
firmly believe that our developed platform will be a high utility testing method towards 
fighting this and future pandemics, helping to end one of the deepest global health, economic 
and humanitarian crises in modern history.  
EXPERIMENTAL PROCEDURES 
Resource Availability 
Lead Contact 
Further information and requests for materials should be directed to and will be fulfilled by 
the Lead Contact, Wei Gao, weigao@caltech.edu.  
Materials Availability  
The materials generated in this study are available from the corresponding author upon 
request.  
Data and Code Availability 
The data used to support the findings of this study are available from the corresponding 
author upon request. 
Materials and Reagents 
1-Pyrenebutyric acid (PBA, 97%), 1H-pyrrole-1-propionic acid (PPA, 97%), 1-ethyl-3-(3-
dimethylamonipropyl)carbodiimide (EDC), N-hydroxysulfosuccinimide (Sulfo-NHS), bovine 
serum albumin (BSA), hydroquinone (HQ), 2-(N-morpholino)ethanesulfonic acid hydrate 
(MES), Tween® 20, sodium thiosulfate, sodium bisulfite and potassium ferrocyanide (II) 
were purchased from Sigma Aldrich. Streptavidin-POD conjugate (Streptavidin-HRP, 
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11089153001) was purchased from Roche. Sodium dihydrogen phosphate, potassium 
hydrogen phosphate, potassium chloride, hydrogen peroxide (30% w/v), sulfuric acid and 
flat-bottom NUNCTM 96-well microplates were purchased from Fisher Scientific. Potassium 
ferricyanide (III) and silver nitrate, iron (III) chloride and 0.1 M PBS (pH 7.4) were 
purchased from Across Organics and Alfa Aesar, respectively. N,N-Dimethylformaide (DMF) 
and Isopropyl alcohol (IPA) were purchased from Fisher Chemical and VWR Chemicals 
respectively. Anti-CRP murine monoclonal antibody and human CRP standard were 
purchased from R&D Systems (DY1707). CRP polyclonal antibody labeled with HRP (PA1-
28329) and 3,3’,5,5’ tetramethylbenzidine (TMB) colorimetric substrate was purchased from 
Invitrogen. Mouse nucleocapsid protein (NP) monoclonal antibody (40143-MM05), SARS-
CoV-2 NP antigen (40588-V08B), SARS-CoV/SARS-CoV-2 nucleocapsid antibody, rabbit 
mAb (40143-R001), SARS-CoV NP antigen (HCoV-OC43; 40643-V07E), SARS-CoV-2 
Spike S1-His Recombinant Protein (HPLC-verified) (40591-V08H) and SARS-CoV Spike 
S1 Protein (S1 Subunit, His Tag) (40150-V08B1) were purchased from Sino Biological. His-
tagged SARS-CoV-2 Spike S1 protein (PNA002), His-Tagged SARS-CoV-2 Nucleocapsid 
protein (PNA006), anti-Spike-RBD fully human mAb (IgG) (S1-IgG, AHA013), anti-NP 
mAb (IgG) (SARS-CoV-2 NP-IgG, AHA009), SARS-CoV antibody-80R (IgG) (CHA001) 
and MERS-CoV antibody-2E6 (IgG) (CHA002) were purchased from Sanyou Bio. Rabbit 
anti-human IgG IgG H&L (HRP) (ab6759), recombinant human BNP (ab87200), rabbit anti-
human IgM mu chain (HRP) (ab97210), goat anti-rabbit IgG H&L (HRP) (ab97051), and 
rabbit polyclonal anti-6X His tag antibody (ab9108) were purchased from Abcam. Human 
Spike-SARS-CoV-2 IgM (S1-IgM, MBS2614311) were purchased from MyBiosource. 
MERS-CoV/SARS-CoV negative control (CI 2601-0101 Z) was purchased from Euroimmun. 
Polyimide film (PI, 125 µm thick) was purchased from DuPont.  
Fabrication of Multiplex Array Electrode 
For four channel graphene sensor fabrication, a PI film was attached onto a supporting 
substrate in a 50 W CO2 laser cutter (Universal Laser System VLS3.50). Selected laser-
cutting parameters were: Power 8.0%, Speed 15%, Points Per Inch (PPI) 1000, in raster mode 
and at focused height. Ag/AgCl reference electrodes (RE) were fabricated by 
electrodeposition in 40 µL of a mixture solution containing silver nitrate, sodium thiosulfate, 
and sodium bisulfite (final concentrations 250 mM, 750 mM and 500 mM, respectively) for 
100 seconds at -0.2 mA, followed by drop-casting 20 µL-aliquot of FeCl3 for 1 minute. 
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Functionalization of the SARS-CoV-2 RapidPlex and Electrochemical Readout 
10 µL-aliquot of 5.0 mM PBA in DMF was drop-casted on the graphene surface and 
incubated for 2 hours at room temperature in a humid chamber. After rinsing with DMF, IPA, 
deionized (DI) water and drying under air flow, electrodes were incubated with 10 µL of a 
mixture solution containing 0.4 M EDC and 0.1 M Sulfo-NHS in 0.025 M MES (pH 6.5) for 
35 minutes at room temperature under humid ambient conditions. Specific antibodies or 
coating protein were covalently attached onto activated surface by drop-casting 5.0 µL of the 
specific reagent (250 µg mL-1 for S1-IgG, S1-IgM and CRP, or 50X dilution for NP, in 0.01 
M phosphate-buffered saline (PBS, pH 7.4)) and incubated for 3 hours at room temperature, 
followed by 90 minutes blocking step with 2.0% BSA prepared in 0.01 M PBS. Subsequently, 
10 µL of the corresponding target analyte prepared in 0.01 M PBS containing 1.0% BSA was 
incubated for 1- or 10 minutes at room temperature and, after one washing step with PBS, 
corresponding detector antibody (HRP labeled or unlabeled) (250X dilution for NP, 2.0 µg 
mL-1 for S1-IgG and S1-IgM, and 1.0 µg mL-1 for CRP) in 0.01 M PBS containing 1.0% 
BSA was incubated for 5 minutes at room temperature. In the case of NP assay, after 
incubating detector antibody and performing corresponding washing step with PBS, 10 µL of 
1.0 µg mL-1 HRP-goat anti rabbit IgG prepared in 0.01 M PBS containing 1.0% BSA was 
incubated for 5 minutes at room temperature. For each type of developed assay, 
amperometric readings were registered at -0.2 V (vs. Ag/AgCl) in 0.05 M sodium phosphate 
buffer (pH 6.0) containing 2.0 mM HQ. The readout signal was obtained in presence of 1.0 
mM H2O2. 
To characterize the morphology and material properties before and after surface modification 
with PBA, SEM images of graphene electrodes were obtained by focused ion beam SEM 
(FIB–SEM, FEI Nova 600 NanoLab).  
Electrochemical Characterization of the SARS-CoV-2 RapidPlex 
Amperometry, open circuit potential-electrochemical impedance spectroscopy (OCP-EIS), 
cyclic voltammetry (CV), and differential pulse voltammetry (DPV) were carried out on a 
CHI820 electrochemical station. The electrochemical setup comprised laser-induced 
graphene electrodes (LGEs) as the working electrodes (WEs), a platinum wire as the counter 
electrode (CE), and a commercial Ag/AgCl electrode as the reference electrode (RE). 
For each type of proposed assay, surface modification after each step was electrochemically 
characterized by DPV and OCP-EIS. Corresponding readings by means of each technique 
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were carried out in 0.01 M PBS (pH 7.4) containing 2.0 mM of K4Fe(CN)6/K3Fe(CN)6 (1:1) 
and under the following detailed conditions: potential range, -0.2 and 0.6 V; pulse width, 0.2 
s; incremental potential, 4 mV; amplitude, 50 mV; frequency range, 0.1–106 Hz; amplitude, 5 
mV. Graphene functionalization methods were evaluated for both CRP and SARS-CoV-2 
specific IgG assays, by comparing current responses obtained after developing each assay on 
both PBA and PPA-graphene, in the absence and in the presence of each of the corresponding 
target biomolecules (tested levels were 50 ng mL-1 for CRP and 500 ng mL-1 for SARS-CoV-
2 specific IgG). Selectivity study was carried out by incubating corresponding interferential 
non-target molecules on the previously functionalized PBA-graphene. Concentration levels 
assayed for each interferent were the same as (or even higher than) the concentration of the 
target molecule in each case. Amperometric signals obtained for each interferent tested were 
compared to the current signals obtained in the absence and in the presence of the 
corresponding target analyte for each type of assay. 
Design and Fabrication of Electronic System for the SARS-CoV-2 RapidPlex 
The 4 channel chronoamperometric measurements were performed by a custom PCB-based 
wireless potentiostat. An Arm Cortex-M4 microcontroller (STM32L432KC; 
STMicroelectronics), and a Bluetooth module (SPBT3.0DP2; STMicroelectronics) were used 
for potentiostat control and wireless communication. A single operational amplifier (AD8605; 
Analog Devices) was used as the control amplifier, and a quad operational amplifier 
(AD8608; Analog Devices) was used as a four transimpedance amplifier to construct the 
potentiostat loop. A series voltage reference (ISL60002; Renesas Electronics) and the MCU’s 
built-in digital to analog converter (DAC) were used to generate the voltage bias across the 
reference and working electrodes. 4 MCU built-in analog-to-digital converter (ADC) 
channels were used to concurrently acquire the measurements.  
Subjects and Procedures 
In compliance with the protocols approved by the Institutional Review Board (no. 19-
089417-292-A2) at the California Institute of Technology (Caltech), the performance of 
SARS-CoV-2 RapidPlex was evaluated in human serum and saliva samples from healthy and 
confirmed COVID-19 infected patients. Serum samples from 10 RT-PCR and IgG/IgM 
serology confirmed COVID-19 patients (age range 24-77 years) and 7 healthy subjects (age 
range 18-65 years) were purchased from BioIVT and Ray Biotech. The severity information 
of the BioIVT samples was provided by the phlebotomists during sample collection. Saliva 
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samples from 5 RT-PCR and IgG/IgM serology test confirmed COVID-19 patients (age 
range 28-46 years) were purchased from BioIVT. 3 healthy saliva samples were used from 
preexisting stocks collected from volunteers prior to the pandemic (recommended tips before 
saliva collection include avoiding foods with high sugar and caffeine content, not eating a 
major meal within 60 minutes of sample collection, and rinsing the mouth with water prior 
sample collection). After receiving, serum and saliva samples were stored at -80 ºC until 
required for its analysis. To perform the analysis of NP, CRP, S1-IgG and S1-IgM, no sample 
treatment was required for both serum and saliva samples; a simple dilution with 0.01 M PBS 
containing 1.0% BSA was performed prior to analysis. 
Determination of SARS-CoV-2 Related Selected Targets Molecules in Serum and Saliva 
Samples 
NP antigen, CRP, and S1-IgG and S1-IgM isotypes were analyzed in commercial serum and 
saliva samples from RT-PCR COVID-19 confirmed positive patients (nserum=10; nsaliva=5) and 
healthy subjects (nserum=7; nsaliva=3). After 100- and 5X dilution of corresponding serum and 
saliva samples in PBS with 1.0% BSA, respectively, 10 µL-aliquot was incubated in each 
WE for 10 minutes at room temperature (25X dilution was used for 1-minute incubation 
study in serum for Figure 5C). After washing step with PBS buffer, corresponding detector 
reagents were incubated in each WE for 5 minutes and subsequent detection was performed. 
Comparison of sensor performance in buffer and diluted body fluids from healthy subjects 
spiked with increasing concentrations of target molecule was performed using CRP as a 
model molecule.  
Validation of Human Samples with the Gold Standard ELISA 
 
ELISA tests for NP, S1-IgG and CRP (selected as model targets) were performed in an 
accuSkan FC Filter-Based Microplate Photometer at a detection wavelength of 450 nm 
according to the manufacturer’s instructions. In brief, plates were coated for 3 hours, shaking 
at 37 ̊C, with 4.0 µg mL-1 of the corresponding capture receptor in each case and blocked 
with PBS containing 1.0% BSA for 2 hours, shaking at 37 ̊C, standards (or properly diluted 
samples), were added to coated microtiter plate wells and incubated for 2 hours, shaking at 
37 ̊C. Next, corresponding HRP-labeled detector antibody was incubated for 30 minutes at 
room temperature. Finally, 100 µL of 3,3’,5,5’-tetramethylbenzidine (TMB) substrate was 
incubated for 15 minutes, and absorbance values were measured immediately after addition 
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of 25 µL of 1 M H2SO4 in each well. Three washings with PBS containing 1.0% BSA were 
performed after each modification step. 
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FIGURE CAPTIONS 
Figure 1. A Wireless Graphene-based Telemedicine Platform (SARS-CoV-2 RapidPlex) 
for Rapid and Multiplex Electrochemical Detection of SARS-CoV-2  in Blood and 
Saliva. 
(A) Schematic illustration of the SARS-CoV-2 RapidPlex multisensor telemedicine platform 
for detection of SARS-CoV-2 viral proteins, antibodies (IgG and IgM), and inflammatory 
biomarker – C-reactive protein (CRP). Data can be wirelessly transmitted to a mobile user 
interface. WE, working electrode; CE, counter electrode; RE, reference electrode. 
(B) Mass-producible laser-engraved graphene sensor arrays. 
(C) Photograph of a disposable and flexible graphene array. 
(D) Image of a SARS-CoV-2 RapidPlex system with a graphene sensor array connected to a 
printed circuit board for signal processing and wireless communication. 
Figure 2. Characterization of Electrochemical Graphene Biosensors Comprising the 
SARS-CoV-2 RapidPlex Platform. 
(A) Scheme detailing the methodology developed for the covalent attachment of the 
corresponding bioreceptor for the specific capture of the target analytes SARS-CoV-2 NP and 
CRP (left), and IgG and IgM isotypes against SARS-CoV-2 S1 protein (right). PBA, 1-
Pyrenebutyric acid; BSA, bovine serum albumin; CAb, capture antibody; PI, polyimide. 
(B) and (C) Differential pulse voltammetry (DPV) and Nyquist plots of a graphene electrode 
in 0.01 M phosphate-buffered saline (PBS, pH 7.4) containing 2.0 mM of 
K4Fe(CN)6/K3Fe(CN)6 (1:1) after each modification step (S1-IgG assay as representative 
example): bare graphene (Bare), functionalization with PBA (PBA), immobilization of 
SARS-CoV-2 S1 protein (Protein), blocking with BSA (BSA), recognition of specific S1-IgG 
(Target), and incubation with enzyme-tagged anti-human IgG antibody (DAb). 
(D) Comparison of amperometric responses and overlaid signal-to-blank (S/B) ratio (black 
lines) for SARS-CoV-2 specific IgG and CRP detection using PBA and 1H-pyrrole-1-
propionic acid (PPA) as linkers for the attachment of the corresponding capture bioreceptors. 
Data are presented as mean ± SD (n = 3).  
(E) Amperometric responses and overlaid S/B ratio (black lines) observed for 0.0 and 500 pg 
mL-1 NP, 0.0 and 250 ng mL-1 SARS-CoV-2 specific IgG and IgM, and 0.0 and 50 ng mL-1 
CRP, with 10, 5 and 1-minute incubation. Data are presented as mean ± SD (n = 3). 
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Figure 3. Evaluation of Analytical Sensor Performance for the Detection of 
Physiological Levels of Target COVID-19 Biomarkers. 
(A) Scheme of sensor preparation for detection of SARS-CoV-2 NP and CRP based on 
double-sandwich and sandwich assay configurations, respectively. CAb, capture antibody; 
DAb, detector antibody; DAb2, secondary detector antibody; HRP, horseradish peroxidase. 
(B) and (C) Calibration curves constructed for NP (B) and CRP (C) detection in phosphate-
buffered saline (PBS, pH 7.4) supplemented with 1.0% BSA. Data are presented as mean ± 
SD (n = 3). 
(D) Scheme of sensor preparation for detection of S1- IgG and S1-IgM isotypes based on 
direct assay configurations.  
(E) and (F) Calibration curves constructed for S1-IgG (E) and S1-IgM (F) isotypes detection 
in phosphate-buffered saline (PBS, pH 7.4) supplemented with 1.0% BSA. Data are presented 
as mean ± SD (n = 3). 
Figure 4. Investigation of the Selectivity and Multiplexed Performance of the Wireless 
SARS-CoV-2 RapidPlex Platform. 
(A) Selective response of NP, S1-IgG and S1-IgM isotypes and CRP sensors against different 
non-target circulating analytes. Interferential molecules were tested at 500 pg mL-1 (with an 
exception of 50 ng mL-1 for CRP), 250 ng mL-1 and 50 ng mL-1 for NP, S1-IgG and S1-IgM, 
and CRP assays, respectively. Data are presented as mean ± SD (n = 3). 
(B) Validation of sample concentrations measured using the designed electrochemical sensor 
against sample concentrations measured using ELISA. 
(C) Block diagram of the SARS-CoV-2 RapidPlex platform. UART, universal asynchronous 
receiver/transmitter; MCU, microcontroller unit; DAC, digital-to-analog converter; ADC, 
analog-to-digital converter. 
(D) Schematic illustration of the graphene sensor array layout. 
(E) Experimental readings obtained with the functionalized SARS-CoV-2 RapidPlex 
platform after incubation of the four WEs with phosphate-buffered saline (PBS, pH 7.4) 
supplemented with 1.0% BSA containing 1.0 ng mL-1 NP (I), 250 ng mL-1 S1-IgG (II), 250 
ng mL-1 S1-IgM (III) and 50 ng mL-1 CRP (IV).  
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Figure 5. Application of SARS-CoV-2 RapidPlex in SARS-CoV-2 Detection in Blood 
and Saliva Samples from COVID-19 Positive and Negative subjects. 
(A and B) Experimental readings obtained with SARS-CoV-2 RapidPlex after 10 minutes 
incubation of the sensor array with serum samples from a representative COVID-19 RT-PCR 
negative (A) and positive patient (B).  
(C) The signal of individual sensor obtained after 1-minute incubation with a serum sample 
from a COVID-19 positive patient (dark color) vs. the signal obtained after 10-minute 
incubation with a serum sample from a COVID-19 negative patient (light color).  
(D) A box-and-whisker plot of measured signal-to-blank ratios (S/B) for NP, S1-IgG, S1-IgM, 
and CRP in RT-PCR confirmed COVID-19 positive (n=5) and negative (n=6) serum samples. 
(E) A box-and-whisker plot of measured signal-to-blank ratios (S/B) for NP, S1-IgG, S1-IgM, 
and CRP in RT-PCR confirmed COVID-19 positive (n=5) and negative (n=3) saliva samples. 
(F) CRP levels in diluted serum samples plotted against given COVID-19 symptom severity, 
with “Healthy” referring to COVID-19 negative patient samples (n=7). Positive COVID-19 
patients classified according to disease severity as asymptomatic (n=2), mild (n=5) and 
moderate (n=2). 
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Table 1. Key Information on an Individual’s COVID-19 Infection Status Provided by 
the SARS-CoV-2 RapidPlex. +, higher than threshold; -, lower than threshold; ||, or.  
Viral 
Antigen IgM IgG CRP Expected Outcome 
- - - - Healthy 
+ + || - - - Infectious, Presymptomatic 
+ + || + - Infectious, Asymptomatic 
+ + || + + Infectious, Symptomatic 
- + + || - + || - Recovered (recently) 
- - + - Recovered (long term) 
- - - + Inflammation/infection not due to COVID-19 
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Progress and Potential 
The need for widespread testing to control the spread of COVID-19 has faced challenges due to 
testing backlogs, limited access to required equipment, and inaccurate assay results. To address 
this, we propose an ultrasensitive and low-cost telemedicine platform − the SARS-CoV-2 
RapidPlex − based on target-specific immunoassays built off laser-engraved graphene for rapid 
and remote assessment of COVID-19 biomarkers (i.e., nucleocapsid protein, anti-spike protein 
IgG and IgM, and C-reactive protein). Multiplex sensing of these targets provides information on 
three key aspects of COVID-19 disease: viral infection, immune response, and disease severity. 
We successfully demonstrated the platform’s applicability using COVID-19 positive and 
negative serum and saliva samples. The SARS-CoV-2 RapidPlex has the potential to quickly and 
effectively triage patients and track infection progression, allowing for the clear identification of 
individuals who are infectious, vulnerable, and/or immune. 
 
Highlights 
• Multiplexed detection of SARS-CoV-2 antigen, antibodies, and C-reactive protein. 
• Low-cost and mass manufacturable platform using laser-engraved graphene. 
• Wireless telemedicine sensing platform with rapid sample-to-answer turnaround. 
• Successful device evaluation in both COVID-19 patient blood and saliva samples. 
 
e-TOC 
The SARS-CoV-2 RapidPlex is developed based on laser-engraved graphene immunosensors to 
electrochemically quantify SARS-CoV-2 nucleocapsid protein, IgG and IgM, and C-reactive 
protein (CRP). The platform is characterized by rapid detection, and high molecular sensitivity, 
selectivity. Pilot study results demonstrate that it can successfully detect these biomarkers in 
COVID-19 positive patient serum and saliva samples. CRP results are well-correlated with 
symptom severity, indicating the potential for this integrated system to be used as a diagnostic 
tool for telemedicine COVID-19 patient care. 
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